Literature DB >> 22928909

Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors.

P Salaj1, P Ovesna, M Penka, U Hedner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22928909     DOI： 10.1111/j.1365-2516.2012.02920.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  5 in total

1.  Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study).

Authors:  Gholamreza Toogeh; Hassan Abolghasemi; Peyman Eshghi; Mohammadreza Managhchi; Mohammadreza Shaverdi-Niasari; Katayoon Karimi; Samin Roostaei; Neda Emran; Alireza Abdollahi
Journal:  Iran J Pathol       Date:  2016

2.  Pain and pain management in haemophilia.

Authors:  Günter Auerswald; Gerry Dolan; Anne Duffy; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Thierry Lambert; Silva Zupančić Šalek
Journal:  Blood Coagul Fibrinolysis       Date:  2016-12       Impact factor: 1.276

3.  Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.

Authors:  Meriem Bensadok; Abdulkareem Almomen; Azzam Alzoebie; Soraya Benchikh El Fegoun; Yasser Wali; Fati Hamzy; Nemra Gaid Mehalhal; Fatiha Grifi; Selma Hamdi; Naima Mesli; Tarek Owaidah; Hossam Ali Saad; Nouredine Sidi Mansour; Hadj Touhami
Journal:  Blood Coagul Fibrinolysis       Date:  2017-03       Impact factor: 1.276

4.  Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.

Authors:  S R Lentz; S Ehrenforth; F Abdul Karim; T Matsushita; K N Weldingh; J Windyga; J N Mahlangu
Journal:  J Thromb Haemost       Date:  2014-07-16       Impact factor: 5.824

5.  The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.

Authors:  Steven R Lentz; Savita Rangarajan; Faraizah A Karim; Philip D Andersen; Per Arkhammar; Gabriela Rosu; Johnny Mahlangu
Journal:  Blood Coagul Fibrinolysis       Date:  2017-04       Impact factor: 1.276
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.